NASDAQ$AGEN

Agenus Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Agenus reported its financial results for the third quarter of 2020.

Agenus reported a net loss of $52 million, or $0.28 per share, for the third quarter of 2020. The company's cash balance at the end of the quarter was $114 million.

  • Ended the third quarter of 2020 with a cash balance of $114 million, compared to $62 million at December 31, 2019.
  • Cash used in operations for the third quarter ended September 30, 2020 was $32 million.
  • Net loss for the quarter was $52 million or $0.28 per share, including non-cash expenses of $18 million.
  • Recognized revenue of $57 million for the nine months ended September 30, 2020, including revenue related to the upfront license fee from the Betta transaction and non-cash royalties earned.

Headline financials

Total Revenue

$14.8M

Previous: $19.9M-25.6%
EPS (adj)

-$5.60

Previous: -$6.60+15.2%
Capital Expenditures

-$2.63M

Previous: -$3.6M+26.9%
Free Cash Flow

-$54.3M

Previous: -$49.9M-8.8%
Net Income

-$51.6M

Previous: -$46.3M-11.6%
Operating Income

-$34.8M

Previous: -$35.9M+3.2%
Gross Profit

$13.9M

Previous: $140K+9843.6%
Cash & Equivalents

$114M

Previous: $93.3M+22.4%
Total Assets

$204M

Previous: $175M+17.0%
Stock-Based Comp

$2.72M

Previous: $3.08M-11.7%

Revenue & EPS history

Agenus · Revenue · Quarterly

$14.8M

Q3 2020-25.6%vs Q3 2019
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

The press release contains forward-looking statements regarding clinical development and regulatory plans and timelines, anticipated corporate milestones, new clinical data and program updates to be presented at SITC and the anticipated commencement of Agenus’ clinical collaboration with Rottapharm.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.7%

Avg return

Earnings day

+0.2%

Avg return

5 days after

+5.4%

Avg return

30 days after

49%

31 / 63 earnings

Positive

+39.9%

Q4 2011

Best reaction

-22.3%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-14.9%-6.3%-19.9%
Q4 2025+5.8%+19.7%+55.8%
Q3 2025+6.3%+9.0%+2.8%
Q1 2025+20.3%+19.6%+77.3%
Q4 2024-4.7%-13.5%-24.7%
Q3 2024-22.3%-30.3%-21.0%
Q2 2024+0.2%-7.3%-2.6%
Q1 2024-11.4%-19.0%+27.9%
Q4 2023-18.0%-15.2%-38.3%
Q3 2023+7.5%-16.7%+3.8%
Q2 2023-5.9%-0.7%-7.4%
Q1 2023-3.1%-10.7%+28.3%
Q4 2022+10.5%-0.6%-12.3%
Q3 2022-15.5%+5.0%+5.0%
Q2 2022+2.3%+13.8%+0.4%
Q1 2022-0.7%+7.2%+7.9%
Q4 2021+13.7%+7.8%-8.9%
Q3 2021+3.6%-7.2%-23.2%
Q2 2021-0.4%+9.2%+13.0%
Q1 2021+4.2%+5.1%+36.6%
Q4 2020-3.0%-6.3%-18.7%
Q3 2020+0.0%+4.9%+0.5%
Q2 2020+12.3%+5.7%+17.4%
Q1 2020-4.2%-3.0%+45.8%
Q4 2019-7.4%-20.6%-8.1%
Q3 2019+13.3%+25.3%+38.2%
Q2 2019+17.8%+24.7%+41.6%
Q1 2019+7.5%+10.2%+1.5%
Q4 2018-3.0%+1.0%-12.2%
Q3 2018+10.1%+5.9%+25.0%
Q2 2018+4.6%+3.5%+16.8%
Q1 2018-14.1%-3.3%-14.4%
Q4 2017+2.1%-1.6%-18.7%
Q3 2017-4.4%+1.6%-1.4%
Q2 2017-2.4%-6.6%-9.7%
Q1 2017+10.5%+10.5%+2.3%
Q4 2016+3.9%+0.3%-14.9%
Q3 2016-21.8%-26.0%-7.1%
Q2 2016+12.6%+12.6%+26.2%
Q1 2016-16.2%
Q4 2015+19.6%
Q3 2015-5.4%
Q2 2015-7.4%
Q1 2015+17.1%
Q3 2014-2.9%
Q2 2014+6.2%
Q1 2014-5.2%
Q4 2013+0.4%
Q3 2013+2.8%
Q2 2013+1.0%
Q1 2013+1.1%
Q4 2012+4.6%
Q3 2012-7.2%
Q2 2012-4.2%
Q1 2011-3.9%
Q1 2012+6.7%
Q4 2011+39.9%
Q3 2011-3.7%
Q2 2011-16.2%
Q4 2010-4.0%
Q3 2010-5.2%
Q2 2010-1.2%
Q1 2010+14.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro